HitGen Forms Immunocology Collaboration with California's Aduro

22:48 EDT 21 Aug 2017 | ChinaBio Today

HitGen of Chengdu and Houston has formed another drug discovery collaboration, this one with Aduro Biotech, an immunocology company based in Berkeley, California. HitGen will employ its very large library of small molecules to discover novel small molecule leads for targets chosen by Aduro. Earlier this year, HitGen established partnerships with Merck, Pfizer, the Scripps Institute and LEO Pharma of Denmark. HitGen will receive an upfront payment, and it will be eligible for milestone payments from Aduro. More details....

Stock Symbols: (NSDQ: ADRO) (NYSE: MRK) (NYSE: PFE)

Share this with colleagues:

Original Article: HitGen Forms Immunocology Collaboration with California's Aduro


More From BioPortfolio on "HitGen Forms Immunocology Collaboration with California's Aduro"

Quick Search


Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...